Oxford, UK – 28 June 2011. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has announced details of its upcoming workshop at the European Cytogenetics Conference 2011, held in Porto, Portugal (2–5 July). Professor Joris Vermeesch, Head of the Laboratory for Cytogenetics and Genome Research at Katholieke Universiteit Leuven will present data obtained using aCGH microarrays co-developed with OGT. The presentation entitled “About inherited pathogenic and de novo benign CNVs”, will discuss the use of aCGH to deliver new insights into the association between copy number variation and a range of developmental disorders. Some of the data to be presented was obtained using a unique custom microarray that combines OGT’s CytoSure™ ISCA 8x60k and CytoSure Syndrome Plus v2 2x105k arrays into a 4x180k format. This design facilitates data sharing between ISCA consortium members and the comparison of new data with legacy data. Additional data generated using this array was presented at the recent European Society of Human Genetics (ESHG) Meeting in Amsterdam by Paul Brady, a PhD student in Professor Vermeesch’s lab. This presentation entitled “The use of array CGH for prenatal diagnosis of foetuses with congenital malformations detected by ultrasound” is available to download on the OGT website.
The new combined array is just one tool developed as part of the successful ongoing relationship between OGT and the Katholieke Universiteit Leuven. Researchers at the University have also recently utilised OGT CytoSure custom designed arrays, CytoSure DNA Labelling Kits and class-leading CytoSure Interpret Software to identify genomic imbalances associated with congenital diaphragmatic hernia (CDH), with the work subsequently published in the journal Prenatal Diagnosis. In addition, studies conducted at the University were instrumental in the development of the CytoSure Aneuploidy array, which allows simple, reliable and cost-effective detection of whole chromosomal imbalances in miscarriage samples. Such examples excellently illustrate how the collaborations formed between OGT and world-class academic institutes are leading to the development of superior tools for use in cytogenetic research. Professor Joris Vermeesch commented: “The complex nature of our work requires a high level of accuracy combined with in-built flexibility. Working with OGT provides both, allowing us to optimise our aCGH design and workflow to generate the best results possible from each individual study.”
Register now for OGT’s ECC workshop.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF
T: +44 (0) 1865 856826
> F: +44 (0) 1865 848684
E: products@ogt.co.uk
W: www.ogt.co.uk
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT delivers tailored biomarker discovery solutions that optimise drug and diagnostic development programmes. With expertise in genomic and proteomic diagnostic biomarkers, OGT provides highly specific customised biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
